Biogen starts layoff round as the Aduhelm maker struggles with Alzheimer’s rollout White House details 4-step plan to keep America open while preparing for future COVID-19 surges Bristol Myers Squibb to consolidate R&D units in San Diego in new complex Smaller smartphone accessory magnets may also pose a threat to pacemakers, defibrillators: AHA study AstraZeneca, Sanofi reveal mixed hand in high-stakes RSV game, with hospitalization miss tarnishing primary endpoint hit Civica Rx to make, distribute low-cost insulin Billionaire Sackler family enters $6B opioid deal with support from holdout states Roche, Sanofi, Novo Nordisk and more pledge support to Ukraine as industry condemns Russian invasion As Russia stacked troops on Ukraine's border, Karuna's trial partners got ready DarioHealth lands $30M deal with Sanofi to expand commercial reach of its digital therapeutics Regeneron loses bid to scrap infringement lawsuit linked to COVID antibody cocktail UT Austin scientists design safer Cas9 with improved CRISPR gene editing accuracy FDA clears Gleamer’s X-ray AI for spotting broken bones Biogen's Aduhelm still has blockbuster potential if everything breaks right: analyst Featured Story | By Angus Liu Biogen has started sending out the layoff letters to some employees in the U.S. as part of the $500 million restructuring plan unveiled in December. read more |
| |
|---|
|
Top Stories By Dave Muoio The government's new National COVID-19 Preparedness Plan has four major goals: to protect against and treat COVID-19, to prepare for new variants of COVID-19, to prevent economic and educational shutdowns and to drive more vaccination outside of the U.S. read more By Kevin Dunleavy Bristol Myers Squibb will soon take up residence in a new R&D campus in San Diego, California, leasing a 427,000 square foot complex in the University Town Center near La Jolla. The agreement will allow BMS to consolidate its R&D units in the area under one roof. read more By Conor Hale If these devices are carried in a chest pocket near or over the heart, they could accidentally switch off implants such as pacemakers and cardioverter defibrillators that are designed to keep a person’s pulse on track. read more By Nick Paul Taylor There’s more trouble in the respiratory syncytial virus (RSV) race. Days after GlaxoSmithKline stopped its maternal vaccine studies, AstraZeneca and Sanofi have revealed their antibody prospect failed to reduce infant hospitalization in a phase 3 clinical trial. read more By Anastassia Gliadkovskaya Civica plans to make three generic insulins, the price of which will be based on the cost of development, production and distribution. read more By Eric Sagonowsky When OxyContin maker Purdue Pharma and its founding family inked a $4.5 billion opioid settlement back in September, the judge overseeing the case called it a "bitter result." Now, thanks to an appeal and extended talks, the settlement just got a lot bigger. read more By Fraiser Kansteiner The contingent of pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing. read more By Max Bayer When Russia began to stack troops along Ukraine's border—up to 190,000 of them—Karuna Therapeutics' partners began to prepare clinical trial participants for the company's schizophrenia treatment in psychiatric hospitals across the country. read more By Rebecca Torrence Chronic care management company DarioHealth signed a $30 million multi-year contract with Sanofi to extend the commercial reach of its digital therapeutics to the pharma giant's health plan clients. read more By Fraiser Kansteiner Pfizer and BioNTech recently emerged from a lawsuit unscathed after Allele Biotechnology and Pharmaceuticals cried patent infringement against a trio of pandemic juggernauts. For Regeneron, however, the legal battle is set to roll on. read more By Angus Liu Scientists at the University of Texas at Austin have refined the Cas9 protein used in the CRISPR gene-editing tool. The new version, dubbed “SuperFi-Cas9,” was thousands of times less likely to perform off-target editing while maintaining the efficiency of on-target editing as the original version. read more By Conor Hale The Paris-based company's computer-assisted diagnostic system aims to help ER physicians as well as orthopedic surgeons and family doctors. read more By Kevin Dunleavy A recent doctors' survey, conducted by RBC Capital Markets, shows a strong market exists for Aduhelm or similar beta-amyloid antibodies. If restrictions are loosened or if Biogen gets a positive readout in a phase 3 trial, the analysts see the potential for $8 billion in peak sales from the company's Alzheimer's franchise. The report comes amid another appeal from Congress to reconsider limiting use of the drug to clinical trials. read more |
